Anadi Mahajan

713 total citations
18 papers, 459 citations indexed

About

Anadi Mahajan is a scholar working on Surgery, Genetics and Epidemiology. According to data from OpenAlex, Anadi Mahajan has authored 18 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 4 papers in Genetics and 3 papers in Epidemiology. Recurrent topics in Anadi Mahajan's work include Neurogenetic and Muscular Disorders Research (4 papers), Congenital Anomalies and Fetal Surgery (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Anadi Mahajan is often cited by papers focused on Neurogenetic and Muscular Disorders Research (4 papers), Congenital Anomalies and Fetal Surgery (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Anadi Mahajan collaborates with scholars based in United Kingdom, United States and Switzerland. Anadi Mahajan's co-authors include Job van der Palen, Neil Barnes, Raj Kumar Sharma, Mike Thomas, Henry Chrystyn, Bruno Delafont, Damon Bass, David A. Roth, Kerry Gairy and Justyna Amelio and has published in prestigious journals such as Journal of Hepatology, Annals of Oncology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Anadi Mahajan

17 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anadi Mahajan United Kingdom 8 159 131 125 77 68 18 459
Marilina Antonelou United Kingdom 9 107 0.7× 37 0.3× 35 0.3× 79 1.0× 25 0.4× 21 251
Akihiro Tsukadaira Japan 11 178 1.1× 84 0.6× 99 0.8× 69 0.9× 33 0.5× 28 434
Baruch D. Jakubovic Canada 9 65 0.4× 22 0.2× 29 0.2× 39 0.5× 9 0.1× 15 338
Álvaro Hernández Vicente Spain 9 43 0.3× 32 0.2× 47 0.4× 54 0.7× 88 1.3× 18 414
Marisa Santostefano Italy 10 192 1.2× 52 0.4× 56 0.4× 22 0.3× 43 0.6× 14 572
Omar Racchi Italy 11 48 0.3× 87 0.7× 28 0.2× 76 1.0× 100 1.5× 19 463
Lisa N. van der Vorm Netherlands 10 71 0.4× 29 0.2× 18 0.1× 32 0.4× 64 0.9× 18 370
Mikhail D. Smirnov United States 11 50 0.3× 54 0.4× 67 0.5× 51 0.7× 83 1.2× 16 494
Derrick Kaufman United States 7 36 0.2× 67 0.5× 35 0.3× 40 0.5× 14 0.2× 9 419
Ruriko Nozawa Japan 14 203 1.3× 19 0.1× 100 0.8× 103 1.3× 41 0.6× 27 527

Countries citing papers authored by Anadi Mahajan

Since Specialization
Citations

This map shows the geographic impact of Anadi Mahajan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anadi Mahajan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anadi Mahajan more than expected).

Fields of papers citing papers by Anadi Mahajan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anadi Mahajan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anadi Mahajan. The network helps show where Anadi Mahajan may publish in the future.

Co-authorship network of co-authors of Anadi Mahajan

This figure shows the co-authorship network connecting the top 25 collaborators of Anadi Mahajan. A scholar is included among the top collaborators of Anadi Mahajan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anadi Mahajan. Anadi Mahajan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Mahajan, Anadi, et al.. (2024). Association of Hepatitis B Surface Antigen Levels With Long‐Term Complications in Chronic Hepatitis B Virus Infection: A Systematic Literature Review. Journal of Viral Hepatitis. 31(11). 746–759. 1 indexed citations
2.
Chase, Dana M., Anadi Mahajan, David A. Scott, Neil Hawkins, & Linda Kalilani. (2024). The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis. BMC Women s Health. 24(1). 179–179. 5 indexed citations
3.
Evans, Rachel, Neil Hawkins, Anadi Mahajan, et al.. (2024). Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy. Advances in Therapy. 41(6). 2414–2434. 9 indexed citations
4.
5.
Chase, Dana M., Anadi Mahajan, David A. Scott, Neil Hawkins, & Linda Kalilani. (2023). Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review. International Journal of Gynecological Cancer. 33(10). 1602–1611. 5 indexed citations
6.
Zierhut, Matthew L., Ahmed Nader, Anadi Mahajan, et al.. (2023). Model-based meta-analysis of pegylated IFN-alpha induced HBsAg loss at end of treatment and 24 weeks post treatment in chronic hepatitis B virus infection. Journal of Hepatology. 78. S1141–S1142. 1 indexed citations
7.
Daigl, Monica, Ksenija Gorni, Rachel Evans, et al.. (2022). How does risdiplam compare with other treatments for Types 1–3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. Journal of Comparative Effectiveness Research. 11(5). 347–370. 23 indexed citations
8.
Chase, Dana M., et al.. (2021). 761P Impact of residual disease on outcomes in patients with ovarian cancer: A meta-analysis. Annals of Oncology. 32. S748–S748. 2 indexed citations
9.
Baranello, Giovanni, Ksenija Gorni, Monica Daigl, et al.. (2021). Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy. Clinical Pharmacology & Therapeutics. 110(6). 1435–1454. 23 indexed citations
10.
Mahajan, Anadi, Justyna Amelio, Kerry Gairy, et al.. (2020). Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 29(9). 1011–1020. 115 indexed citations
11.
Amelio, Justyna, et al.. (2020). P0857BURDEN OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN DIALYSIS AND NON-DIALYSIS-DEPENDENT PATIENTS IN EUROPE: A REVIEW OF PUBLISHED EVIDENCE. Nephrology Dialysis Transplantation. 35(Supplement_3). 1 indexed citations
12.
Révil, Cédric, Markus Niggli, Sammy Chebon, et al.. (2019). Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Current Medical Research and Opinion. 35(12). 2079–2087. 21 indexed citations
13.
Daigl, Monica, Anna Kotzeva, Ksenija Gorni, et al.. (2019). PRO12 HOW DOES RISDIPLAM COMPARE IN INFANTILE ONSET SPINAL MUSCOLAR ATROPHY (SMA)? PRELIMINARY INDIRECT TREATMENT COMPARISONS BASED ON FIREFISH PART 1 DATA. Value in Health. 22. S843–S843. 5 indexed citations
14.
Amelio, Justyna, et al.. (2019). 87 Mapping disease severity and progression of renal involvement in patients with systemic lupus erythematosus. Abstracts. A63–A64. 1 indexed citations
15.
Chrystyn, Henry, Job van der Palen, Raj Kumar Sharma, et al.. (2017). Device errors in asthma and COPD: systematic literature review and meta-analysis. npj Primary Care Respiratory Medicine. 27(1). 22–22. 160 indexed citations
16.
Mahadevan, Amitkumar, et al.. (2015). Some Extremely-Low WER/BER Performance Simulation Results for Linear Block Codes via DAIS.
17.
Mahajan, Anadi, et al.. (2013). Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers. International Journal of Rheumatology. 2013. 1–9. 29 indexed citations
18.
Raza, Kaisar, Bhupinder Singh, Anadi Mahajan, et al.. (2010). Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. Journal of drug targeting. 19(4). 293–302. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marilina Antonelou Breakdown of academic impact, for papers by Akihiro Tsukadaira Breakdown of academic impact, for papers by Baruch D. Jakubovic Breakdown of academic impact, for papers by Álvaro Hernández Vicente Breakdown of academic impact, for papers by Marisa Santostefano Breakdown of academic impact, for papers by Omar Racchi Breakdown of academic impact, for papers by Lisa N. van der Vorm Breakdown of academic impact, for papers by Mikhail D. Smirnov Breakdown of academic impact, for papers by Derrick Kaufman Breakdown of academic impact, for papers by Ruriko Nozawa
Rankless by CCL
2026